ANI Pharmaceuticals launches generic duloxetine delayed-release capsules in the US
ANI Pharmaceuticals announced the launch of duloxetine delayed-release capsules in 20, 30 and 60 mg strengths, according to a company press release.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Pharmaceutical company ANI Pharmaceuticals has announced the launch of a generic duloxetine delayed-release capsule in 20, 30 and 60 mg strengths. The product is the generic version of the reference drug Cymbalta.
According to the press release distributed via GlobeNewswire, the company expects the launch to add an option for patients in a market with limited competition and to support a stable supply. Chief Executive Nikhil Lalwani said the company was providing 'another alternative of a widely used therapy'. Based on IQVIA data for the 12 months to August 2026, U.S. annual sales of the product totaled about $247 million.
why it matters
For investors, the launch matters mainly for pricing in niche generic segments: when only a few manufacturers compete, pressure on prices is usually weaker, which affects supplier revenue. The news concerns a single company and does not change the outlook for the pharmaceutical sector as a whole.
tags
instruments
sources
- ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules — globenewswire.com, 19 October 2026 at 10:55 UTC
- Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules — Reuters, 19 October 2026 at 11:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗